Local inflammation in axial spondyloarthritis (axSpA) leads to the release of collagen metabolites from the disease-affected tissue. We investigated whether collagen metabolites were associated with disease activity and could distinguish non-radiographic(nr)-axSpA from ankylosing spondylitis (AS). A total of 193 axSpA patients (nr-axSpA, n = 121 and AS, n = 72) and asymptomatic controls (n = 100) were included. Serum levels of metalloproteinase (MMP)-degraded collagen type I (C1M), type II (C2M), type III (C3M) and type IV (C4M2) were quantified by enzyme-linked immunosorbent assay (ELISA). All metabolites were higher in axSpA than in controls (all p < 0.001). Serum levels of C1M, C3M, and C4M2 were increased in AS compared to nr-axSpA (43.4 ng/mL vs. 34.6; p < 0.001, 15.4 vs. 12.8; p = 0.001, and 27.8 vs. 22.4; p < 0.001). The best metabolite to differentiate between axSpA and controls was C3M (AUC 0.95; specificity 92.0, sensitivity 83.4). C1M correlated with ASDAS-CRP in nr-axSpA (ρ = 0.37; p < 0.001) and AS (ρ = 0.57; p < 0.001). C1M, C3M, and C4M2 were associated with ASDAS-CRP in AS and nr-axSpA after adjustment for age, gender, and disease duration. Serum levels of collagen metabolites were significantly higher in AS and nr-axSpA than in controls. Moreover, the present study indicates that collagen metabolites reflect disease activity and are useful biomarkers of axSpA.

Department of Rheumatology Nordic Bioscience Biomarkers and Research Herlev Denmark

Institute of Rheumatology and Department of Rheumatology 1st Faculty of Medicine Charles University Prague Na Slupi 4 Prague 128 50 Czech Republic

Erratum v

Sci Rep. 2020 Aug 19;10(1):14133. doi: 10.1038/s41598-020-71093-9. PubMed

Zobrazit více v PubMed

Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390:73–84. doi: 10.1016/S0140-6736(16)31591-4. PubMed DOI

Sieper J, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann. Rheum. Dis. 2009;68:ii1–ii44. PubMed

van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheumatol. 1984;27:361–368. doi: 10.1002/art.1780270401. PubMed DOI

Maksymowych WP, et al. MRI evidence of structural changes in the sacroiliac joints of patients with non-radiographic axial spondyloarthritis even in the absence of MRI inflammation. Arthritis Res. Ther. 2017;19:126. doi: 10.1186/s13075-017-1342-9. PubMed DOI PMC

de Winter JJ, van Mens LJ, van der Heijde D, Landewe R, Baeten DL. Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis. Arthritis Res. Ther. 2016;18:196. doi: 10.1186/s13075-016-1093-z. PubMed DOI PMC

van der Heijde D, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann. Rheum. Dis. 2017;76:978–991. doi: 10.1136/annrheumdis-2016-210770. PubMed DOI

Dougados M, et al. Rate and predisposing factors for sacroiliac joint radiographic progression after a two-year follow-up period in recent-onset spondyloarthritis. Arthritis Rheumatol. 2016;68:1904–1913. doi: 10.1002/art.39666. PubMed DOI PMC

Poddubnyy D, et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann. Rheum. Dis. 2011;70:1369–1374. doi: 10.1136/ard.2010.145995. PubMed DOI

Wang R, Gabriel SE, Ward MM. Progression of nonradiographic axial spondyloarthritis to ankylosing spondylitis: a population-based cohort study. Arthritis Rheumatol. 2016;68:1415–1421. doi: 10.1002/art.39542. PubMed DOI PMC

Anaya JM, et al. Personalized medicine. Closing the gap between knowledge and clinical practice. Autoimmun. Rev. 2016;15:833–842. doi: 10.1016/j.autrev.2016.06.005. PubMed DOI

Marzo-Ortega H, Gaffney KM, Gaffney K. Defining the target: clinical aims in axial spondyloarthritis. Rheumatology. 2018;57:vi18–vi22. doi: 10.1093/rheumatology/key176. PubMed DOI PMC

Maksymowych WP. Biomarkers for diagnosis of axial spondyloarthritis, disease activity, prognosis, and prediction of response to therapy. Front. Immunol. 2019;10:305. doi: 10.3389/fimmu.2019.00305. PubMed DOI PMC

Baraliakos X, Braun J. Non-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences? RMD Open. 2015;1:e000053. doi: 10.1136/rmdopen-2015-000053. PubMed DOI PMC

Kjelgaard-Petersen C, et al. Synovitis biomarkers: ex vivo characterization of three biomarkers for identification of inflammatory osteoarthritis. Biomarkers. 2015;20:547–556. doi: 10.3109/1354750X.2015.1105497. PubMed DOI PMC

Mattey DL, et al. Association of cytokine and matrix metalloproteinase profiles with disease activity and function in ankylosing spondylitis. Arthritis Res. Ther. 2012;14:R127. doi: 10.1186/ar3857. PubMed DOI PMC

Maksymowych WP, et al. Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum. 2007;56:1846–1853. doi: 10.1002/art.22589. PubMed DOI

Bay-Jensen AC, et al. Ankylosing spondylitis is characterized by an increased turnover of several different metalloproteinase-derived collagen species: a cross-sectional study. Rheumatol. Int. 2012;32:3565–3572. doi: 10.1007/s00296-011-2237-8. PubMed DOI

Siebuhr AS, et al. Serological identification of fast progressors of structural damage with rheumatoid arthritis. Arthritis Res. Ther. 2013;15:R86. doi: 10.1186/ar4266. PubMed DOI PMC

Leeming D, et al. A novel marker for assessment of liver matrix remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M) Biomarkers. 2011;16:616–628. doi: 10.3109/1354750X.2011.620628. PubMed DOI

Bay-Jensen AC, et al. Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM–increased serum CIIM in subjects with severe radiographic osteoarthritis. Clin. Biochem. 2011;44:423–429. doi: 10.1016/j.clinbiochem.2011.01.001. PubMed DOI

Siebuhr AS, Bay-Jensen AC, Karsdal MA, Lories RJ, de Vlam K. CRP and a biomarker of type I collagen degradation, C1M, can differentiate anti-inflammatory treatment response in ankylosing spondylitis. Biomark. Med. 2016;10:197–208. doi: 10.2217/bmm.15.119. PubMed DOI

Vassiliadis E, et al. Measurement of CO3-610, a potential liver biomarker derived from matrix metalloproteinase-9 degradation of collagen type III, in a rat model of reversible carbon-tetrachloride-induced fibrosis. Biomark. Insights. 2011;6:49–58. doi: 10.4137/BMI.S6347. PubMed DOI PMC

Sand JM, et al. MMP mediated degradation of type IV collagen alpha 1 and alpha 3 chains reflects basement membrane remodeling in experimental and clinical fibrosis–validation of two novel biomarker assays. PLoS One. 2013;8:e84934. doi: 10.1371/journal.pone.0084934. PubMed DOI PMC

Bay-Jensen AC, et al. Circulating protein fragments of cartilage and connective tissue degradation are diagnostic and prognostic markers of rheumatoid arthritis and ankylosing spondylitis. PLoS One. 2013;8:e54504. doi: 10.1371/journal.pone.0054504. PubMed DOI PMC

Rudwaleit M, et al. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum. 2009;60:717–727. doi: 10.1002/art.24483. PubMed DOI

Althoff CE, et al. Active inflammation and structural change in early active axial spondyloarthritis as detected by whole-body MRI. Ann. Rheum. Dis. 2013;72:967–973. doi: 10.1136/annrheumdis-2012-201545. PubMed DOI

de Winter JJ, Paramarta JE, de Jong HM, van de Sande MG, Baeten DL. Peripheral disease contributes significantly to the level of disease activity in axial spondyloarthritis. RMD Open. 2019;5:e000802. doi: 10.1136/rmdopen-2018-000802. PubMed DOI PMC

Sun S, et al. The active form of MMP-3 is a marker of synovial inflammation and cartilage turnover in inflammatory joint diseases. BMC Musculoskelet. Disord. 2014;15:93. doi: 10.1186/1471-2474-15-93. PubMed DOI PMC

Liu KG, He QH, Tan JW, Liao GJ. Expression of TNF-alpha, VEGF, and MMP-3 mRNAs in synovial tissues and their roles in fibroblast-mediated osteogenesis in ankylosing spondylitis. Genet. Mol. Res. 2015;14:6852–6858. doi: 10.4238/2015.June.18.28. PubMed DOI

Kiltz U, et al. The degree of spinal inflammation is similar in patients with axial spondyloarthritis who report high or low levels of disease activity: a cohort study. Ann. Rheum. Dis. 2012;71:1207–1211. doi: 10.1136/annrheumdis-2011-200508. PubMed DOI

Ruyssen-Witrand A, et al. Relationships between ultrasound enthesitis, disease activity and axial radiographic structural changes in patients with early spondyloarthritis: data from DESIR cohort. RMD Open. 2017;3:e000482. doi: 10.1136/rmdopen-2017-000482. PubMed DOI PMC

Siebuhr AS, et al. Is radiographic progression in radiographic axial spondyloarthritis related to matrix metalloproteinase degradation of extracellular matrix? RMD Open. 2018;4:e000648. doi: 10.1136/rmdopen-2018-000648. PubMed DOI PMC

Gudmann NS, et al. Type I and III collagen turnover is increased in axial spondyloarthritis and psoriatic arthritis. Associations with disease activity and diagnostic capacity. Clin. Exp. Rheumatol. 2017;35:653–659. PubMed

Kang KY, Jung JY, Hong YS, Ju JH, Park SH. Positive correlation between inflammation on sacroiliac joint MRI and serum C-terminal telopeptide of type-I collagen in ankylosing spondylitis but not in non-radiographic axial spondyloarthritis. Clin. Exp. Rheumatol. 2017;35:415–422. PubMed

Jacques P, et al. Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells. Ann. Rheum. Dis. 2014;73:437–445. doi: 10.1136/annrheumdis-2013-203643. PubMed DOI

Wang R, Ward MM. Epidemiology of axial spondyloarthritis: an update. Curr. Opin. Rheumatol. 2018;30:137–143. doi: 10.1097/BOR.0000000000000475. PubMed DOI PMC

Rueda-Gotor J, et al. Subclinical atherosclerosis is not increased in patients with non-radiographic axial spondyloarthritis. Clin. Exp. Rheumatol. 2016;34:159–160. PubMed

Dragsbaek K, et al. Matrix metalloproteinase mediated type I collagen degradation - an independent risk factor for mortality in women. EBioMedicine. 2015;2:723–729. doi: 10.1016/j.ebiom.2015.04.017. PubMed DOI PMC

Haroon NN, Paterson JM, Li P, Inman RD, Haroon N. Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study. Ann. Intern. Med. 2015;163:409–416. doi: 10.7326/M14-2470. PubMed DOI

Sun LM, et al. Increased risk of cancer for patients with ankylosing spondylitis: a nationwide population-based retrospective cohort study. Scand. J. Rheumatol. 2014;43:301–306. doi: 10.3109/03009742.2013.863969. PubMed DOI

Siebuhr, A. S. et al. Metabolites of C-reactive protein and vimentin are associated with disease activity of axial spondyloarthritis. Clin. Exp. Rheumatol. Feb 11 Epub ahead of print (2019). PubMed

van der Heijde D, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann. Rheum. Dis. 2009;68:1811–1818. doi: 10.1136/ard.2008.100826. PubMed DOI

Calin A, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J. Rheumatol. 1994;21:2281–2285. PubMed

Doward LC, et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann. Rheum. Dis. 2003;62:20–26. doi: 10.1136/ard.62.1.20. PubMed DOI PMC

Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol group. Ann. Med. 2001;33:337–343. doi: 10.3109/07853890109002087. PubMed DOI

Maksymowych WP, et al. Spondyloarthritis research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. Arthritis Rheum. 2005;53:703–709. doi: 10.1002/art.21445. PubMed DOI

Hermann KG, Braun J, Fischer T, Reisshauer H, Bollow M. Magnetic resonance tomography of sacroiliitis: anatomy, histological pathology, MR-morphology, and grading. Radiologe. 2004;44:217–228. doi: 10.1007/s00117-003-0992-6. PubMed DOI

Wanders AJ, et al. What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the outcome measures in rheumatology clinical trials filter. Arthritis Rheum. 2004;50:2622–2632. doi: 10.1002/art.20446. PubMed DOI

Barascuk N, et al. Development and validation of an enzyme-linked immunosorbent assay for the quantification of a specific MMP-9 mediated degradation fragment of type III collagen–A novel biomarker of atherosclerotic plaque remodeling. Clin. Biochem. 2011;44:900–906. doi: 10.1016/j.clinbiochem.2011.04.004. PubMed DOI

Veidal SS, et al. Assessment of proteolytic degradation of the basement membrane: a fragment of type IV collagen as a biochemical marker for liver fibrosis. Fibrogenesis Tissue Repair. 2011;4:22. doi: 10.1186/1755-1536-4-22. PubMed DOI PMC